Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Heike Heuer has a total of 157 co-authors. Here are the top co-authors by number of shared publications:

  • Steffen Mayerl

    Leibniz Institute on Aging/Fritz Lipmann Institute, 07745 Jena, Germany

    5 shared publications
  • Dagmar Führer

    Department of Endocrinology, Diabetes and Metabolism, Centre for Endocrine Medicine (CEM) and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University Duisburg-Essen, Essen, Germany

    4 shared publications
  • Anita Boelen

    Amsterdam Gastrointestinal Endocrinology Metabolism, 1105 AZ Amsterdam, The Netherlands

    3 shared publications
  • Boyka Markova

    Department of Endocrinology, Diabetes and Metabolism, Centre for Endocrine Medicine (CEM) and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University Duisburg-Essen, Essen, Germany

    3 shared publications
  • Boyka Markova

    Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany

    3 shared publications
  • Markus Schwaninger

    Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism, University of Lubeck, Lubeck, Germany

    3 shared publications

Latest Publications

  • Gene Replacement in Tanycytes Ameliorates Neurological Consequences of Mct8 Deficiency in Mice

    by Adriana Arrulo Pereira, Helge Müller-Fielitz, Julica Inderhees, Eva Novoa, Akila Chandrasekar, Ümit Özorhan, Sreekala Nampoothiri, Yvon Mbouamboua, Riccardo Dore, Heike Heuer, et al.

    Background: MCT8 transports thyroid hormones into the central nervous system. A genetic deficiency of MCT8 leads to hypothyroidism in the brain and severe neurological symptoms, a condition known as Allan–Herndon–Dudley syndrome (AHDS). Replacing MCT8 with gene therapy could effectively treat AHDS, but the most suitable target cell is yet to be identified. Since endogenous Mct8 is expressed by the glial tanycytes that form the blood–cerebrospinal fluid barrier in the hypothalamus, we tested the efficacy of tanycyte-directed gene therapy. Methods: We used Mct8 −/− mice on an Oatp1c1 −/− background (double knockout, DKO) as a model of AHDS to avoid compensation of OATP1C1 for MCT8 deficiency. After DKO mice received an intracerebroventricular injection of an adeno-associated virus encoding Mct8 at postnatal day 40, we investigated endocrine and neurological parameters of the disease. Results: The gene therapy approach restored Mct8 expression and normalized thyrotropin releasing hormone-induced signaling in DKO tanycytes, suggesting intact MCT8 function in these cells. Although MCT8 rescue in tanycytes did not correct the overactive hypothalamus–pituitary–thyroid axis in DKO mice, it improved triiodothyronine concentrations and gene expression in the cortex. Furthermore, it counteracted the reduction in brain weight in DKO mice. Conclusions: Gene therapy targeting tanycytes improves neurological parameters in mice with Mct8 deficiency. Further research is needed to determine whether this approach could be used to treat AHDS.

  • Loss of Thyroid Hormone Transporters MCT8 and OATP1C1 in Mouse Oligodendroglia Cells Results in a Delayed Oligodendrocyte Maturation and Myelination

    by Joshua-Joel Richter, Boyka Markova, Beyza Atalay, Anita Boelen, Dagmar Führer, Steffen Mayerl, Heike Heuer

    Background: Due to an impaired thyroid hormone (TH) transport across brain barriers, inactivation of the murine TH transporters Mct8/Oatp1c1 causes a profound TH deficiency of the CNS that greatly impacts neural development and function. Since oligodendrocyte maturation and myelination are dependent on local TH signaling, Mct8/Oatp1c1 double knockout (DKO) mice exhibit a persistent state of hypomyelination. Yet, to which extent Mct8/Oatp1c1 inactivation also affects TH transport into oligodendroglia cells has not been addressed. Here, we studied oligodendrocyte maturation and myelination in mice lacking Mct8/Oatp1c1 specifically in oligodendroglia lineage (OL) cells and compared their phenotype with that of control and DKO animals. Method: Conditional Mct8/Oatp1c1 mutants were crossed with mice expressing constitutively Cre-recombinase under the control of the Olig2 promoter to inactivate both transporters in OL cells (so-called OL CKO mice). Neural maturation and myelination were assessed by immunofluorescence (IF) and fluorescence in situ hybridization (FISH) studies at different postnatal time points. Oligodendrocyte precursor cells (OPCs), premyelinating, and myelinating oligodendrocytes were visualized by coimmunolabeling. Results: OL CKO mice exhibited normal serum TH concentrations and hypothalamic Trh transcript levels. Quantification of neuronal TH-target gene transcript levels ( Rc3; Klf9; Pde10a ) revealed no alterations. Abundance of myelin sheaths-related proteins Mbp and Cnp was significantly reduced in OL CKO mice at postnatal day P12 but reached normal levels at P21 and P120. Quantification of OPC, premyelinating, and myelinating oligodendrocytes disclosed a strongly reduced number of mature OL at P6 and P12, while cell numbers normalized in adult OL CKO mice. Conclusions: Inactivation of murine TH transporters Mct8/Oatp1c1 in OL cells causes a delayed oligodendroglia maturation and myelination. These findings highlight a physiologically relevant function of Mct8/Oatp1c1 in developmental oligodendrogenesis and myelin formation. In contrast to the persistent myelination defect seen in central hypothyroid DKO mice, OL CKO mice exhibit only a transient oligodendrocyte differentiation impairment and transient hypomyelination. These observations indicate the presence of additional, yet unknown, TH transporters that ultimately enable cellular TH entry into oligodendroglia cells even in the absence of Mct8/Oatp1c1.

  • Open Access

    Thyrotropin-releasing hormone neurons of different hypothalamic nuclei increase energy expenditure

    by Andreea Constantinescu, Akila Chandrasekar, Lena Kleindienst, Luca Höhne, Natalia Da Silva Lima, Marius Richter, Vanessa Neve, Frauke Spiecker, Ines Stölting, Wiebke Brandt, et al.

    Several neuronal populations in the hypothalamus and brainstem express thyrotropin-releasing hormone (TRH). While TRH neurons in the paraventricular nucleus (PVN) regulate the thyroid axis, the roles of other TRH-producing neurons remain largely unknown. Here we investigate the role of TRH neurons in the PVN, the dorsomedial hypothalamus (DMH), the medial preoptic area (MPA), and the rostral raphe pallidus (RPa) for metabolism in mice. Selective activation of these populations using chemogenetics in mice revealed that TRH neurons of the hypothalamus increase food intake and influence energy homeostasis in different ways. Specifically, TRH neurons in the PVN and DMH enhance brown adipose tissue activity via a polysynaptic circuit, while MPA-located neurons increase locomotor activity and maintain cold tolerance. These effects were independent of the thyroid axis, demonstrating that TRH neurons have distinct, subtype-specific ways to increase energy expenditure beyond regulating the thyroid axis in mice.


  • Open Access

    Thyroid hormone receptor α signaling shapes innate and adaptive immune responses during viral infection

    by Christina Wenzek, Torben Knuschke, G Sebastian Hönes, Anita Boelen, Robert Klopfleisch, Denise Zwanziger, Heike Heuer, Astrid M Westendorf, Lars C Moeller, Dagmar Führer

    Objective: Thyroid hormones (TH) are well-known regulators of the immune system. However, the precise immunomodulatory mechanisms of TH action in immune cells remain elusive. In a previous study, an essential role of the TH receptor α (TRα) in regulatory T cell (Treg) immunity was demonstrated, affecting Treg activation at steady state. The present study therefore aimed to unravel the biological relevance of altered TRα action in protective immune responses during disease. Methods: To assess the role of TRα action in immune responses, especially T cell responses, during disease, different TRα signaling mouse models (TRαKO, complete lack of TRα signaling; TRαGS, lack of canonical signaling) were challenged with influenza virus A/PR8/34, and in-depth immune phenotyping was performed. Results: Upon influenza virus infection, TRαGS mice, which lack canonical TRα signaling, showed prolonged survival and reduced disease severity, correlating with enhanced anti-inflammatory Treg and decreased pro-inflammatory CD4 and CD8 T cell responses. The loss of TRα action in TRαKO mice was related to elevated viral titers upon influenza virus infection, which correlated with increased inflammatory monocyte responses early during infection. Conclusion: The present study demonstrates a complex role of TRα signaling in protective immune responses during disease, with distinct effects on innate and adaptive immune cells. By exploring the understudied link between the endocrine and immune systems, this study provides novel evidence for the role of TH as modulators of immunity.


  • Open Access

    msiFlow: automated workflows for reproducible and scalable multimodal mass spectrometry imaging and microscopy data analysis

    by Philippa Spangenberg, Sebastian Bessler, Lars Widera, Jenny Bottek, Mathis Richter, Stephanie Thiebes, Devon Siemes, Sascha D. Krauß, Lukasz G. Migas, Siva Swapna Kasarla, et al.

    Multimodal imaging by matrix-assisted laser desorption ionisation mass spectrometry imaging (MALDI MSI) and microscopy holds potential for understanding pathological mechanisms by mapping molecular signatures from the tissue microenvironment to specific cell populations. However, existing software solutions for MALDI MSI data analysis are incomplete, require programming skills and contain laborious manual steps, hindering broadly applicable, reproducible, and high-throughput analysis to generate impactful biological discoveries. Here, we present msiFlow, an accessible open-source, platform-independent and vendor-neutral software for end-to-end, high-throughput, transparent and reproducible analysis of multimodal imaging data. msiFlow integrates all necessary steps from raw data import to analytical visualisation along with state-of-the-art and self-developed algorithms into automated workflows. Using msiFlow, we unravel the molecular heterogeneity of leukocytes in infected tissues by spatial regulation of ether-linked phospholipids containing arachidonic acid. We anticipate that msiFlow will facilitate the broad applicability of MSI in multimodal imaging to uncover context-dependent cellular regulations in disease states.


  • Open Access

    Triiodothyronine treatment in mice improves stroke outcome and reduces blood–brain barrier damage

    by Daniel Ullrich, Dagmar Führer, Heike Heuer, Steffen Mayerl, Steffen Haupeltshofer, Linda-Isabell Schmitt, Markus Leo, Rebecca D Szepanowski, Tim Hagenacker, Markus Schwaninger, et al.

    Objective: Thyroid hormones control a variety of processes in the central nervous system and influence its response to different stimuli, such as ischemic stroke. Post-stroke administration of 3,3′,5-triiodo-L-thyronine (T3) has been reported to substantially improve outcomes, but the optimal dosage and time window remain elusive. Methods: Stroke was induced in mice by transient middle cerebral artery occlusion (tMCAO), and T3 was administered at different doses and time points before and after stroke. Results: We demonstrated a dose-dependent protective effect of T3 reducing infarct volumes with an optimal T3 dosage of 25 μg/kg. In addition, we observed a time-dependent effectiveness that was most profound when T3 was administered 1 h after tMCAO (P < 0.001), with a gradual reduction in efficacy at 4.5 h (P = 0.066), and no reduction in infarct volumes when T3 was injected with an 8-h delay (P > 0.999). The protective effect of acute T3 treatment persisted for 72 h post-tMCAO (P < 0.01) and accelerated the recovery of motor function by day 3 (P < 0.05). In-depth investigations further revealed reduced cerebral edema and diminished blood–brain barrier leakage, indicated by reduced extravasation of Evans blue and diminished aquaporin-4 expression. Conclusion: Our findings suggest that T3 may be a promising intervention for ischemic stroke in the acute phase.


  • Open Access

    Sciatic nerve analysis in thyroid hormone transporters Mct8 and Oatp1c1 knockout mice

    by Steffen Mayerl, Andrea Alcaide Martin, Reinhard Bauer, Heike Heuer

    Objective: Mutations in the thyroid hormone (TH) transporter monocarboxylate transporter 8 (MCT8) cause Allan–Herndon–Dudley syndrome (AHDS), a severe form of psychomotor retardation with muscle hypoplasia and spastic paraplegia as key symptoms. These abnormalities have been attributed to impaired TH transport across brain barriers and into neural cells, thereby affecting brain development and function. Likewise, Mct8/Oatp1c1 (organic anion-transporting polypeptide 1c1) double knockout (M/Odko) mice, a well-established murine AHDS model, display a strongly reduced TH passage into the brain as well as locomotor abnormalities. To which extent the peripheral nervous system is affected by combined MCT8/OATP1C1 deficiency has not been addressed. Methods: Using the sciatic nerve as a model, we studied the spatiotemporal expression of TH transporters as well as the sciatic thyroidal state, sciatic nerve myelination and function in M/Odko mice by immunofluorescence, qPCR, Western blotting and electrophysiology. Results: We detected MCT8 protein expression in sciatic nerve axons, whereas OATP1C1 expression was observed in a subset of endothelial cells early in postnatal development. The absence of MCT8 and OATP1C1 did not alter the thyroidal state of isolated nerves at P12. Moreover, electrophysiological studies did not disclose any significant alteration in sciatic nerve signal propagation parameters in adult M/Odko mice. Although Schwann cell numbers were similar, Western blot analysis showed a mild form of hypermyelination in adult M/Odko mice. Conclusions: Altogether, our data point to a largely unaffected sciatic nerve structure and function in the absence of MCT8 and OATP1C1.


  • Open Access

    Toward a treatment for thyroid hormone transporter MCT8 deficiency – achievements and challenges

    by Boyka Markova, Steffen Mayerl, Heike Heuer

    Patients with an inactive thyroid hormone (TH) transporter MCT8 (Allan–Herndon–Dudley Syndrome, AHDS) display severe neurological impairments and motor disabilities, indicating an indispensable function of MCT8 in facilitating TH access to the human brain. Consequently, the CNS of AHDS patients appears to be in a TH deficient state, which greatly compromises proper neural development and function. Another hallmark of this disease is that patients exhibit elevated serum T3 levels, leading to a hyperthyroid situation in peripheral tissues. Several treatment strategies have been developed and evaluated in preclinical mouse models as well as in patients. Here, we discuss these different therapeutic approaches to overcome MCT8 deficiency and summarize the current achievements and challenges in improving brain maturation in the absence of MCT8.


  • 3,3′,5-Triiodothyroacetic Acid Transporters

    by Zhongli Chen, Sena Yildiz, Boyka Markova, Linda J. de Rooij, Selmar Leeuwenburgh, Timo Hamers, Robin P. Peeters, Heike Heuer, Marcel E. Meima, W. Edward Visser

    Introduction Thyroid hormone transporters are essential for thyroid hormones to enter target cells. Monocarboxylate transporter MCT8 is a key transporter and expressed at the blood-brain barrier, in neural cells and many other tissues. Patients with MCT8 deficiency have severe neurodevelopmental delays due to cerebral hypothyroidism and chronic sequelae of peripheral thyrotoxicosis. The T3 analog 3,3,5-triiodothyroacetic acid (TRIAC) rescued neurodevelopmental features in animal models mimicking MCT8 deficiency and improved key metabolic features in patients with MCT8 deficiency. However, the identity of the transporter(s) that facilitate TRIAC transport are unknown. Here, we screened candidate transporters that are expressed at the human blood-brain barrier and/or brain-cerebrospinal fluid barrier and known thyroid hormone transporters for TRIAC transport. Materials and methods Plasma membrane expression was determined by cell surface biotinylation assays. Intracellular accumulation of 1 nM TRIAC was assessed in COS-1 cells expressing candidate transporters in Dulbecco's phosphate buffered saline (DPBS)/0.1% glucose or Dulbecco's modified Eagle's medium (DMEM) with or without 0.1% bovine serum albumin (BSA). Expression of Slc22a8 was determined by fluorescent in situ hybridization (FISH) in brain sections from wild-type and Mct8/Oatp1c1 knock-out mice at postnatal day 12, 21 and 120. Results Fifty-nine plasma membrane transporters were selected for screening of TRIAC accumulation (n=40 based on expression at the human blood-brain barrier and/or brain-cerebrospinal fluid barrier and having small organic molecules as substrates; n=19 known thyroid hormone transporters). Screening of the selected transporter panel showed that 18 transporters facilitated significant intracellular accumulation of TRIAC in DPBS/0.1% glucose or DMEM in the absence of BSA. In the presence of BSA, substantial transport was noted for SLCO1B1 and SLC22A8 (in DPBS/0.1% glucose and DMEM) and SLC10A1, SLC22A6 and SLC22A24 (in DMEM). The zebrafish and mouse orthologues of these transporters similarly facilitated intracellular accumulation of TRIAC. Highest Slc22a8 mRNA expression was detected in mouse brain capillary endothelial cells and choroid plexus epithelial cells at early postnatal time points, but wasreduced at P120. Conclusions Human SLC10A1, SLCO1B1, SLC22A6, SLC22A8 and SLC22A24 as well as their mouse and zebrafish orthologues are efficient TRIAC transporters. These findings contribute to the understanding of TRIAC treatment in patients with MCT8 deficiency and animal models thereof.


  • Open Access

    Cone photoreceptor differentiation regulated by thyroid hormone transporter MCT8 in the retinal pigment epithelium

    by Ye Liu, Lily Ng, Hong Liu, Heike Heuer, Douglas Forrest

    The key role of a thyroid hormone receptor in determining the maturation and diversity of cone photoreceptors reflects a profound influence of endocrine signaling on the cells that mediate color vision. However, the route by which hormone reaches cones remains enigmatic as cones reside in the retinal photoreceptor layer, shielded by the blood–retina barrier. Using genetic approaches, we report that cone differentiation is regulated by a membrane transporter for thyroid hormone, MCT8 (SLC16A2), in the retinal pigment epithelium (RPE), which forms the outer blood–retina barrier. Mct8 -deficient mice display hypothyroid-like cone gene expression and compromised electroretinogram responses. Mammalian color vision is typically facilitated by cone types that detect medium-long (M) and short (S) wavelengths of light but Mct8 -deficient mice have a partial shift of M to S cone identity, resembling the phenotype of thyroid hormone receptor deficiency. RPE-specific ablation of Mct8 results in similar shifts in cone identity and hypothyroid-like gene expression whereas reexpression of MCT8 in the RPE in Mct8 -deficient mice partly restores M cone identity, consistent with paracrine-like control of thyroid hormone signaling by the RPE. Our findings suggest that in addition to transport of essential solutes and homeostatic support for photoreceptors, the RPE regulates the thyroid hormone signal that promotes cone-mediated vision.